AU2002228608A1 - Amidated glucagon-like peptide-1 - Google Patents

Amidated glucagon-like peptide-1

Info

Publication number
AU2002228608A1
AU2002228608A1 AU2002228608A AU2860802A AU2002228608A1 AU 2002228608 A1 AU2002228608 A1 AU 2002228608A1 AU 2002228608 A AU2002228608 A AU 2002228608A AU 2860802 A AU2860802 A AU 2860802A AU 2002228608 A1 AU2002228608 A1 AU 2002228608A1
Authority
AU
Australia
Prior art keywords
amidated
glucagon
peptide
amidated glucagon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002228608A
Inventor
Richard Dennis Dimarchi
Wolfgang Glaesner
Rohn Lee Junior Millican
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2002228608A1 publication Critical patent/AU2002228608A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
AU2002228608A 2000-12-13 2001-11-30 Amidated glucagon-like peptide-1 Abandoned AU2002228608A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25525100P 2000-12-13 2000-12-13
US60/255,251 2000-12-13
PCT/US2001/043167 WO2002048192A2 (en) 2000-12-13 2001-11-30 Amidated glucagon-like peptide-1

Publications (1)

Publication Number Publication Date
AU2002228608A1 true AU2002228608A1 (en) 2002-06-24

Family

ID=22967502

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2002228608A Abandoned AU2002228608A1 (en) 2000-12-13 2001-11-30 Amidated glucagon-like peptide-1
AU2002233929A Abandoned AU2002233929A1 (en) 2000-12-13 2001-12-06 Compositions of peptide crystals
AU2002239262A Abandoned AU2002239262A1 (en) 2000-12-13 2001-12-06 Compositions of peptide crystals

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2002233929A Abandoned AU2002233929A1 (en) 2000-12-13 2001-12-06 Compositions of peptide crystals
AU2002239262A Abandoned AU2002239262A1 (en) 2000-12-13 2001-12-06 Compositions of peptide crystals

Country Status (4)

Country Link
US (1) US7199217B2 (en)
EP (1) EP1351984A2 (en)
AU (3) AU2002228608A1 (en)
WO (3) WO2002048192A2 (en)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03005135A (en) 2000-12-13 2003-12-04 Lilly Co Eli Chronic treatment regimen using glucagon-like insulinotropic peptides.
EP1412384B1 (en) 2001-06-28 2007-12-26 Novo Nordisk A/S Stable formulation of modified glp-1
EP2277889B1 (en) 2001-12-21 2014-07-09 Human Genome Sciences, Inc. Fusion proteins of albumin and interferon beta
US20050260259A1 (en) * 2004-04-23 2005-11-24 Bolotin Elijah M Compositions for treatment with glucagon-like peptide, and methods of making and using the same
DE60335608D1 (en) * 2002-02-27 2011-02-17 Pharmain Corp COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS AND OTHER MATERIALS AND METHOD FOR THE PRODUCTION AND USE THEREOF
US7635463B2 (en) * 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
US7790681B2 (en) 2002-12-17 2010-09-07 Amylin Pharmaceuticals, Inc. Treatment of cardiac arrhythmias with GLP-1 receptor ligands
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US8008255B2 (en) 2003-05-30 2011-08-30 Amylin Pharmaceuticals, Inc. Methods and compositions for enhanced transmucosal delivery of peptides and proteins
CN102940879B (en) * 2003-06-03 2017-06-06 诺沃挪第克公司 Stabilized pharmaceutical peptide compositions
WO2004105790A1 (en) * 2003-06-03 2004-12-09 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
CA2527743A1 (en) * 2003-06-03 2004-12-09 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
JP5518282B2 (en) * 2003-09-01 2014-06-11 ノヴォ ノルディスク アー／エス Stable peptide formulation
CN104826116A (en) 2003-11-20 2015-08-12 诺沃挪第克公司 Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
US8710181B2 (en) 2004-08-31 2014-04-29 Novo Nordisk A/S Use of tris(hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins
JP5175103B2 (en) * 2004-11-12 2013-04-03 ノヴォ ノルディスク アー／エス Stable peptide formulation
WO2006069779A1 (en) * 2004-12-30 2006-07-06 F. Hoffmann-La Roche Ag Preparing of peptides with excellent solubility
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
EP2441460A1 (en) * 2005-06-30 2012-04-18 Ipsen Pharma GLP-1 pharmaceutical compositions
WO2007056362A2 (en) 2005-11-07 2007-05-18 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
CN100374462C (en) * 2005-11-21 2008-03-12 大连帝恩生物工程有限公司 Gerobriecin pancrease glucagon peptidel (SGLP-1), its preparation and use
KR101872061B1 (en) 2005-12-19 2018-06-27 파마인 코포레이션 Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
EP2573111A1 (en) 2006-04-20 2013-03-27 Amgen Inc. GLP-1 compounds
DE602007009377D1 (en) 2006-05-30 2010-11-04 Intarcia Therapeutics Inc SECONDARY FLOW MODULATOR WITH AN INTERNAL CHANNEL FOR AN OSMOTIC OUTPUT SYSTEM
KR101200728B1 (en) 2006-08-09 2012-11-13 인타르시아 세라퓨틱스 인코포레이티드 Osmotic delivery system and piston assemblies
US20120214965A1 (en) * 2011-02-23 2012-08-23 Elona Biotechnologies Glargine proinsulin and methods of producing glargine insulin analogs therefrom
US10100098B2 (en) 2006-12-13 2018-10-16 Stelis Biopharma Private Limited Insulin production methods and proinsulin constructs
MX2009006564A (en) 2007-01-05 2009-06-26 Univ Indiana Res & Tech Corp Glucagon analogs exhibiting enhanced solubility in physiological ph buffers.
KR20090119876A (en) 2007-02-15 2009-11-20 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Glucagon/glp-1 receptor co-agonists
AU2008244523B2 (en) * 2007-04-23 2012-02-16 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
US7960336B2 (en) 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8563527B2 (en) * 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
US8981047B2 (en) 2007-10-30 2015-03-17 Indiana University Research And Technology Corporation Glucagon antagonists
ES2558155T3 (en) 2007-10-30 2016-02-02 Indiana University Research And Technology Corporation Compounds showing glucacon antagonist activity and GLP-1 agonist
US20090176892A1 (en) 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
WO2009155257A1 (en) 2008-06-17 2009-12-23 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability physiological ph buffers
SG192405A1 (en) 2008-06-17 2013-08-30 Univ Indiana Res & Tech Corp Gip-based mixed agonists for treatment of metabolic disorders and obesity
PA8830501A1 (en) 2008-06-17 2010-07-27 Univ Indiana Res & Tech Corp GLUCAGON / GLP-1 RECEIVER CO-AGONISTS
JP2012512903A (en) 2008-12-19 2012-06-07 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション Amide glucagon superfamily peptide prodrug
SG176858A1 (en) 2009-06-16 2012-02-28 Univ Indiana Res & Tech Corp Gip receptor-active glucagon compounds
SI2462246T1 (en) 2009-09-28 2018-01-31 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
US20110097386A1 (en) * 2009-10-22 2011-04-28 Biodel, Inc. Stabilized glucagon solutions
ES2583259T3 (en) 2009-12-01 2016-09-20 Novo Nordisk A/S New alpha-amidant peptidyl alpha-hydroxyglycine liases
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
EP2528618A4 (en) 2010-01-27 2015-05-27 Univ Indiana Res & Tech Corp Glucagon antagonist - gip agonist conjugates and compositions for the treatment of metabolic disorders and obesity
WO2011112709A1 (en) * 2010-03-09 2011-09-15 Elan Pharma International Limited Alcohol resistant enteric pharmaceutical compositions
EP2569000B1 (en) 2010-05-13 2017-09-27 Indiana University Research and Technology Corporation Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
CA2797089A1 (en) 2010-05-13 2011-11-17 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
MX2012014576A (en) 2010-06-24 2013-02-21 Univ Indiana Res & Tech Corp Amide based glucagon superfamily peptide prodrugs.
BR112013014942B1 (en) 2010-12-16 2020-01-28 Novo Nordisk As solid compositions for administration, and their uses
MA34885B1 (en) 2010-12-22 2014-02-01 Indiana Unversity Res And Technology Corp GLUCAGON ANALOGS HAVING A GIP RECEPTOR ACTIVITY
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
ES2612278T3 (en) 2011-04-12 2017-05-16 Novo Nordisk A/S GLP-1 double-acylated derivatives
US9156902B2 (en) 2011-06-22 2015-10-13 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
BR112013032717A2 (en) 2011-06-22 2017-01-24 Univ Indiana Res & Tech Corp glucagon / glp-1 receptor coagonists
CA2847246A1 (en) 2011-11-17 2013-05-23 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
KR102072202B1 (en) 2012-03-22 2020-01-31 노보 노르디스크 에이/에스 Compositions of glp-1 peptides and preparation thereof
HUE042757T2 (en) 2012-03-22 2019-07-29 Novo Nordisk As Compositions comprising a delivery agent and preparation thereof
WO2013170636A1 (en) 2012-05-18 2013-11-21 爱德迪安（北京）生物技术有限公司 Protein and protein conjugate for diabetes treatment, and applications thereof
ES2871328T3 (en) 2012-06-20 2021-10-28 Novo Nordisk As Tablet formulation comprising a peptide and a delivery agent
CA2877358A1 (en) 2012-06-21 2013-12-27 Indiana University Research And Technology Corporation Glucagon analogs exhibiting gip receptor activity
PT2991671T (en) 2013-05-02 2018-11-05 Novo Nordisk As Oral dosing of glp-1 compounds
CN112043835B (en) 2013-12-06 2022-10-21 韩捷 Bioreversible introducing group for nitrogen and hydroxyl-containing drugs
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
KR20240042548A (en) 2015-06-03 2024-04-02 인타르시아 세라퓨틱스 인코포레이티드 Implant placement and removal systems
MA53353A (en) 2016-05-16 2021-06-09 Intarcia Therapeutics Inc GLUCAGON RECEPTOR SELECTIVE POLYPEPTIDES AND METHODS FOR THEIR USE
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
EP3565580B1 (en) 2017-01-03 2024-03-06 i2o Therapeutics, Inc. Continuous administration of exenatide and co-adminstration of acetaminophen, ethinylestradiol or levonorgestrel
PE20211202A1 (en) 2017-08-24 2021-07-05 Novo Nordisk As COMPOSITIONS OF GLP-1 AND ITS USES
PL3746111T3 (en) 2018-02-02 2024-01-15 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
MX2021004185A (en) 2018-10-11 2021-09-08 Intarcia Therapeutics Inc Human amylin analog polypeptides and methods of use.
PE20221575A1 (en) 2020-02-18 2022-10-06 Novo Nordisk As PHARMACEUTICAL FORMULATIONS

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4347374A (en) * 1980-07-21 1982-08-31 Merck & Co., Inc. Acid addition salts of N-trityl-α-fluoromethylhistidine enantiomer derivatives
ATE110083T1 (en) 1986-05-05 1994-09-15 Gen Hospital Corp INSULINOTROPIC HORMONE.
US5120712A (en) * 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5118666A (en) * 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
JP3262329B2 (en) 1990-01-24 2002-03-04 アイ． バックレイ，ダグラス GLP-1 analog useful for the treatment of diabetes
CA2084061A1 (en) 1991-04-09 1992-10-10 Arthur M. Felix Growth hormone releasing factor analogs
DK36392D0 (en) 1992-03-19 1992-03-19 Novo Nordisk As USE OF CHEMICAL COMPOUND
PL176007B1 (en) 1992-06-15 1999-03-31 Scios Inc Novel derivatives of polypeptide glp-1
NZ250844A (en) 1993-04-07 1996-03-26 Pfizer Treatment of non-insulin dependant diabetes with peptides; composition
US6284727B1 (en) * 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
WO1995005848A1 (en) 1993-08-24 1995-03-02 Novo Nordisk A/S Protracted glp-1
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US6380357B2 (en) * 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
CA2336112A1 (en) 1998-06-30 2000-01-13 Flemming Manique Seeding crystals for the preparation of peptides or proteins
WO2001057084A1 (en) * 2000-01-31 2001-08-09 Novo Nordisk A/S Crystallisation of a glp-1 analogue
US20030204063A1 (en) * 2000-08-02 2003-10-30 Denis Gravel Modified biological peptides with increased potency
SI1724284T1 (en) * 2000-12-07 2009-12-31 Lilly Co Eli GLP-1 fusion proteins

Also Published As

Publication number Publication date
WO2002047715A2 (en) 2002-06-20
AU2002239262A1 (en) 2002-06-24
WO2002047715A3 (en) 2003-01-30
US7199217B2 (en) 2007-04-03
AU2002233929A1 (en) 2002-06-24
US20040132647A1 (en) 2004-07-08
WO2002048192A3 (en) 2003-08-07
EP1351984A2 (en) 2003-10-15
WO2002048183A2 (en) 2002-06-20
WO2002048192A2 (en) 2002-06-20
WO2002048183A3 (en) 2003-06-05

Similar Documents

Publication Publication Date Title
AU2002228608A1 (en) Amidated glucagon-like peptide-1
AU2002322403A1 (en) Glucagon-like peptide-1 analogs
AU6479101A (en) Glucagon-like peptide-1 analogs
AU2003239478A1 (en) Modified glucagon-like peptide-1 analogs
AU2001284418A1 (en) Novel polypeptide
AU8441801A (en) Novel polypeptide
GB0015761D0 (en) Polypeptide
AU2001288220A1 (en) Hyperglycosylated polypeptides
GB0127017D0 (en) New polypeptide
AU2001266336A1 (en) Body-buried electrode
AU2002211324A1 (en) Oxidoreductases
GB0124559D0 (en) New polypeptide
GB0120704D0 (en) Polypeptide
AU2002224056A1 (en) Novel polypeptide
GB0027537D0 (en) New polypeptide
AU2001248535A1 (en) Limit switch
AU2002231050A1 (en) Oxidoreductases
GB0012199D0 (en) New polypeptide
GB0013239D0 (en) Polypeptide
AU2001234855A1 (en) Neuropeptide-like polypeptide zpep17
AU2002225532A1 (en) Silver-dispersing polypeptides
AUPR112700A0 (en) Peptide nitroanilides
GB0009060D0 (en) New polypeptide
GB0019859D0 (en) New polypeptide
GB0030501D0 (en) New polypeptide